Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 4 out of 5 65.57

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Caps

How do you think NBIX will perform against the market?

Add Stock to CAPS Watchlist

All Players

325 Outperform
45 Underperform
 

All-Star Players

87 Outperform
6 Underperform
 

Wall Street

5 Outperform
3 Underperform
 

Top NBIX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Traced (< 20)
Submitted February 09, 2018

not only can ingrezza be used in TD but also TS,HD,PDD, schizophrenia, etc.. If ingrezza expand its uses to those indications(which it eventually will), we can see ingrezza do a base MINIMIUM of 5B in sales.. also analysts have already projected… More

zzlangerhans (99.78)
Submitted September 10, 2012

Neurocrine has been turning in solid pipeline progress for several years now but they haven't had much success holding gains in the share price. Now that the phase III trial of elagolix is in progress I expect at least a year before all 875 patients… More

NBIX VS S&P 500 (SPY)

Fools bullish on NBIX are also bullish on:

Fools bearish on NBIX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NBIX.

Recs

0
Member Avatar Bigsef77 (68.55) Submitted: 1/8/2019 2:52:48 PM : Outperform Start Price: $53.71 NBIX Score: +41.40

Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
[Zacks]
Zacks Equity Research
,Zacks•January 7, 2019

Neurocrine Biosciences, Inc. NBIX provided preliminary sales guidance for Ingrezza pertaining to the fourth quarter of 2018 and the full year along with an update on its pipeline candidates.

2018 Preliminary Results

Based on unaudited financial results, Neurocrine expects Ingrezza sales for the full year to be approximately $409 million, reflecting a staggering increase of 250.8% from the prior-year level. The company estimates Ingrezza for the final quarter to be approximately $130 million, which is also significantly higher than the year-earlier level. The company guided preliminary total prescriptions for Ingrezza to be approximately 22,900 and 71,500 for the fourth quarter and full year, respectively.

Ingrezza is Neurocrine’s only marketed drug, which received an FDA approval in 2017. It is the first medicine approved in the United States for treating adults with tardive dyskinesia (TD). The drug is also being investigated for Tourette syndrome and has been granted an Orphan Drug Designation by the FDA for the same.

Shares of Neurocrine have lost 4% in the past year, narrower than the industry’s decline of 17.8%.

Recs

0
Member Avatar TMFTypeoh (94.77) Submitted: 5/23/2018 11:05:32 AM : Outperform Start Price: $94.25 NBIX Score: -13.08

Lots to like about this mid cap biotech

Recs

1
Member Avatar Traced (< 20) Submitted: 2/8/2018 9:24:17 PM : Outperform Start Price: $43.27 NBIX Score: +77.47

not only can ingrezza be used in TD but also TS,HD,PDD, schizophrenia, etc.. If ingrezza expand its uses to those indications(which it eventually will), we can see ingrezza do a base MINIMIUM of 5B in sales.. also analysts have already projected elagolix to do over 5B in sales with indications in endometriosis & uterine fibroids... ingrezza& elagolix combined could see 10b+ in peak annual sales but yet NBIX continues to trade below a 15B mcap.. also, neurocrines, CAH compound despite a small market could also be another blockbuster.. lastly, opicapone, is a best in class COMT inhibitor and is a crucial product for pharma's developing products in PD as L-dopa continues to be the SOC..specialty drug companies like VRTX, ALXN, BMRN trade at valuations from 15b-45B with sales of 1.5B- 3.5B.. with the same potential, we can see NBIX eventually trade at those valuations or at least 200+ PPS by 2019..

Leaderboard

Find the members with the highest scoring picks in NBIX.

Score Leader

gsm1999

gsm1999 (72.61) Score: +3,423.33

The Score Leader is the player with the highest score across all their picks in NBIX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
gsm1999 72.61 3/8/2010 Outperform 5Y $2.30 +3,566.09% +142.75% +3,423.33 0 Comment
awsumrocker 89.92 3/10/2010 Outperform 3M $2.35 +3,488.09% +142.22% +3,345.86 0 Comment
stockamuteur 70.46 4/8/2010 Outperform 5Y $2.57 +3,180.93% +135.16% +3,045.77 0 Comment
Tadpole85 79.71 1/5/2010 Outperform 1Y $2.68 +3,046.27% +144.90% +2,901.37 0 Comment
borcobob 73.89 12/28/2009 Outperform 3Y $2.82 +2,890.07% +145.68% +2,744.39 0 Comment
royeknox 72.53 8/10/2009 Outperform 5Y $3.03 +2,682.84% +176.73% +2,506.11 0 Comment
MicroOptions 52.85 4/15/2010 Outperform 5Y $3.10 +2,620.00% +129.25% +2,490.75 0 Comment
MicroMikey 63.10 4/15/2010 Outperform 5Y $3.10 +2,620.00% +129.25% +2,490.75 0 Comment
minifesto 74.49 1/2/2009 Outperform 3Y $3.21 +2,526.79% +212.09% +2,314.70 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. foolshand < 20 7/27/2009 Outperform 3W $3.25 +2,494.46% +184.71% +2,309.75 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackOppenheimer 70.63 6/19/2013 Outperform NS $12.97 +550.12% +67.49% +482.62 0 Comment
TrackUltraLong < 20 4/10/2013 Underperform NS $11.85 +611.56% +76.48% -535.08 1 Comment
TrackDeutscheSec 85.90 3/16/2012 Outperform NS $8.74 +864.76% +97.60% +767.16 0 Comment
TrackPoisedTo < 20 3/13/2012 Underperform 5Y $8.12 +938.42% +100.53% -837.90 0 Comment
TrackMKMPartners 88.89 8/9/2011 Outperform NS $6.07 +1,289.13% +141.19% +1,147.94 0 Comment
TrackZacks < 20 6/16/2010 Outperform 3M $5.37 +35.20% +23.40% +11.79 11/9/2012 @ $7.26 1 Comment
TrackLeerinkSwan 97.80 5/28/2008 Underperform NS $4.70 +1.28% +0.22% -1.06 5/28/2008 @ $4.76 0 Comment
TrackBearStearns < 20 12/14/2007 Underperform NS $4.81 +52.81% -6.67% -59.47 4/17/2012 @ $7.35 0 Comment
TrackJefferies 81.48 12/13/2007 Underperform NS $5.20 +1,521.54% +95.83% -1,425.71 0 Comment
TrackSoros 85.33 9/30/2007 Outperform NS $10.00 +743.20% +90.46% +652.74 1 Comment
TrackLehmanBros < 20 1/17/2007 Outperform NS $12.32 -59.25% -5.38% -53.88 2/14/2008 @ $5.02 0 Comment
TrackJimCramer 85.40 4/4/2006 Outperform 3W $63.15 +33.52% +127.51% -93.99 0 Comment

Advertisement